![]() |
|
|
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
2To whom correspondence should be addressed. E-mail: pg37g{at}nih.gov.
Cancer prevention remains the ideal strategy for reducing the burden of cancer on society. Progress in cancer prevention has been accelerated as prevention clinical trials are completed and reported. A promising strategy is the identification of cancer risk factors through epidemiologic and experimental research with lifestyle and medical approaches that allow translation of clinical trial results to clinical practice. A major focus of cancer prevention clinical trials has been on modulation of hormones and nutritional modifications using natural or synthetic bioactive food components for breast and prostate cancer. Breast cancer prevention clinical trials have investigated the role of estrogen antagonists with agents such as tamoxifen, raloxifene, and newer agents such as aromatase inhibitors and bioactive food components. Among the promising bioactive food components being investigated at the National Cancer Institute in prevention clinical trials to reduce breast cancer risk are indole-3-carbinol, sulforaphanes, phytoestrogen isoflavones, perillyl alcohol, and green tea polyphenols. Prostate cancer prevention trials have focused on hormone modulation with the 5-
-reductase inhibitor finasteride and bioactive food components such as selenium and vitamin E. Soy isoflavones, green tea polyphenols, and doxercalciferol also are being investigated for prostate cancer prevention. Future prevention clinical trials will rely on multidisciplinary medical approaches that bring together expertise in many fields to address disease across the cancer spectrum. Nutritional science can play an important role in this effort through the use of new and emerging technologies to better understand the influence of bioactive food components on the genes, proteins, and cellular processes that are associated with cancer risk.
KEY WORDS: cancer prevention clinical trials breast cancer prostate cancer
This article has been cited by other articles:
![]() |
T. Jahangir and S. Sultana Perillyl Alcohol Protects Against Fe-NTA-Induced Nephrotoxicity and Early Tumor Promotional Events in Rat Experimental Model Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 439 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Blanco-Aparicio, L. Perez-Gallego, B. Pequeno, J. F.M. Leal, O. Renner, and A. Carnero Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer Carcinogenesis, March 1, 2007; 28(3): 584 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Lin, Y.-L. Tsai, M.-T. Huang, Y.-P. Lu, C.-T. Ho, S.-F. Tseng, and S.-C. Teng Inhibition of estradiol-induced mammary proliferation by dibenzoylmethane through the E2-ER-ERE-dependent pathway Carcinogenesis, January 1, 2006; 27(1): 131 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Haddad, G. A. Azar, S. Groom, and M. Boivin Natural Health Products, Modulation of Immune Function and Prevention of Chronic Diseases Evid. Based Complement. Altern. Med., December 1, 2005; 2(4): 513 - 520. [Abstract] [Full Text] [PDF] |
||||